FDA revises biosimilar guidelines for clearer drug labelling

[cafead]

via The US Food and Drug Administration (FDA) released a draft guidance giving drug manufacturers recommendations for biosimilar and interchangeable biosimilar products, detailing tips for drafting label prescription information, on 15 September.

article source